MutaMap™ | Mutational Activity Map

ProImmune introduces MutaMap™ high-throughput service

 for mutational activity maps of therapeutic proteins

 

Next generation protein engineering technology

 for improved drug candidate decision making

 

 

Oxford, UK 12 December 2017: ProImmune, a leader in services for understanding immune responses, today announced the introduction of MutaMap™, a new high-throughput assay service for understanding the impact of point mutations on protein therapeutic activity, including monoclonal antibodies. MutaMap™ provides a high-throughput service, with high-quality output data, to help decide which individual point mutations to pursue and enable better protein engineering decisions to be made, prior to committing a drug candidate to a clinical program.

 

MutaMap™ is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting each of the 19 possible amino acid alternatives in at each position in a protein sequence, one by one. Each position of a protein of interest is altered by site-directed mutagenesis, expressed and changes in affinity or activity measured using cell-free in vitro translation of proteins and solution titration assays. These methods avoid the use of surrogate measurements for affinity or activity and have been optimized for high-throughput processing of samples without compromising on readout accuracy. The technology is particularly suited for investigating a range of the ligand-binding interactions, from high-affinity monoclonal antibodies down to the high-femtomolar range where other approaches, such as surface plasmon resonance (SPR), struggle to deliver results in high throughput.

 

MutaMap™ can deliver a high-throughput mutagenesis project for exploring 500-2000 mutations in approximately 8-12 weeks and deliver a heat map for the protein sequence of interest, showing which point mutations lead to an increase, decrease, or no change in affinity (or other activity), or non-function of the protein of interest when interacting with one, or more, of its binding partners. This effectively reveals which mutations are likely permissible or favourable for protein engineering and provides a novel tool for making informed decisions across a range of key developability objectives. These can include cherry picking mutations to improve activity, de-immunization, altering cross-species reactivity, improved humanization or provision of other engineered features, stability and manufacturability, prolonging half-life and developing unique new composition of matter IP.

 

MutaMap™ is the first service ProImmune is offering in the area of protein engineering. The technology is complementary to the company’s existing technologies for assessing the antigenicity of therapeutic proteins and can be readily combined with ProImmune’s leading ProMap® and ProScern® T cell assays, ProPresent® Antigen Presentation Assays and ProImmune REVEAL® MHC-peptide binding assays.

 

Nikolai Schwabe, CEO of ProImmune commented:MutaMap™ is a key new service in our portfolio that addresses a major unmet need for our customers to make informed protein engineering decisions on a broad range of developability issues such as managing the immunogenicity risk of therapeutic proteins, with confidence that the function of the candidate protein will be maintained or even be improved.

 

For further information visit www.proimmune.com.

 

ENDS

 

Notes to Editors:

 

About ProImmune - www.proimmune.com

ProImmune offers unique solutions for immunology research and biologics drug development through integrated systems for antigen characterization, immunogenicity testing, immune monitoring and protein developability engineering. ProImmune is committed to helping its partners achieve success by offering novel industry leading technologies for developing better therapies faster.

 

For more information, please contact

 

At ProImmune:

Jeremy Fry
Tel: +44 (0) 870 042 7279
Email: enquiries@proimmune.com

 

Media enquiries:

Sarah Jeffery
Zyme Communications Ltd
Tel: +44 (0) 7771 730 919
Email: sarah.jeffery@zymecommunications.com